2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Transplantation, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Immunodeficiency, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

6075 Preclinical efficacy and safety evaluation of SPK-8011QQ, an activated protein C-resistant factor VIII gene therapy for hemophilia A

Nina Frey, PhD, Nicolas Receveur2, Michel Enderlin-Paput3, Anastasia Gemelli4, Jamie Albiez5, Anna Kiialainen, PhD6, Lindsey George, MD7, Tovo David8
1 F. Hoffmann-La Roche Ltd, Basel, Switzerland
2 F. Hoffmann-La Roche Ltd, Basel, Switzerland
3 F. Hoffmann-La Roche Ltd, Basel, Switzerland
4 F. Hoffmann-La Roche Ltd, Basel, Switzerland
5 F. Hoffmann-La Roche Ltd, Basel, Switzerland
6 F. Hoffmann-La Roche Ltd, Basel, Switzerland
7 Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 F. Hoffmann-La Roche Ltd, Basel, Switzerland

SPK-8011QQ is a next-generation hemophilia A (HA) gene therapy encoding a B-domain deleted (BDD) human factor (F)VIII R336Q/R562Q variant (FVIII-QQ) resistant to activated protein C (aPC) cleavage, thereby enhancing FVIII function while maintaining the A2-domain mechanism of inactivation. To support the ongoing phase IIb SPK-8011QQ-201 study (NCT07226206), we evaluated the hemostatic potential and pro-thrombotic profile of FVIII-QQ using complementary in vitro and in vivo preclinical models.

Previous studies showed enhanced FVIII-QQ function compared with wild-type BDD human FVIII (FVIII-WT) under aPC-sensitive in vitro conditions, and improved hemostatic efficacy of adeno-associated viral (AAV)-derived FVIII-QQ in a tail clip bleeding model (Frey, ASH 2025; Sternberg, Nat Commun 2024) and in recombinant FVIII protein studies (Wilhelm, Blood 2021). To extend these findings to FVIII expression levels analogous to those observed in the SPK-8011 trial of 25 participants (NCT03003533/NCT03432520; George, ISTH 2024), we used the tail vein transection (TVT) model, a milder bleeding challenge than the tail clip bleeding model, to assess hemostatic activity at FVIII levels closer to those anticipated clinically. We dosed FVIII knockout mice with AAV vector to express FVIII-WT or FVIII-QQ, to achieve chromogenic FVIII activity of between 5% and 40%. We found that FVIII-QQ was associated with reduced cumulative bleeding time compared with FVIII-WT in the TVT model, even at low FVIII activities, consistent with enhanced hemostatic function.

We next assessed whether the hemostatic activity of FVIII-QQ resulted in disproportionate procoagulant activity when combined with bypassing agents. In aPC-sensitive thrombin generation assays using human HA plasma, FVIII-QQ showed significantly higher residual thrombin generation than FVIII-WT in the absence of bypassing agents, consistent with its resistance to aPC-mediated inactivation (Wilhelm, Blood 2021; Frey, ASH 2025). We then combined FVIII-QQ or FVIII-WT with 2 alternative bypassing agents—recombinant FVIIa (rVIIa) or activated prothrombin complex concentrate (aPCC)—that are administered to manage breakthrough bleeds in people with HA with inhibitors. For both FVIII-QQ and FVIII-WT, rFVIIa increased thrombin generation additively, whereas aPCC produced a synergistic increase. Despite the higher residual thrombin generation observed with FVIII-QQ alone, thrombin generation in the presence of either bypassing agent was not significantly different between FVIII-QQ and FVIII-WT. These findings suggest that the enhanced hemostatic activity of FVIII-QQ does not disproportionately amplify the bypassing agent-mediated procoagulant effect relative to FVIII-WT.      

Finally, we performed a ferric chloride carotid artery injury model to evaluate in vivo thrombogenicity in HA mice expressing AAV-derived FVIII-QQ or FVIII-WT. Occlusion was measured by assessing blood flow in this model. Blood flow decreased with FVIII-WT activity across groups, with the strongest response observed in animals receiving recombinant hFVIII at approximately 300% FVIII activity. Across mean FVIII activities of 22–330% for FVIII-QQ and 27–232% for FVIII-WT, no statistically significant differences in blood flow reduction, near-occlusive events, or occlusion kinetics were observed, and FVIII-QQ responses remained with the range of the 100% recombinant FVIII control.

Together, these preclinical efficacy and safety studies demonstrate enhanced hemostatic activity of FVIII-QQ compared with FVIII-WT, without evidence of an increased preclinical prothrombotic profile or an amplified procoagulant effect in combination with bypassing agents. These data provide additional nonclinical support for the ongoing clinical evaluation of FVIII-QQ expression following administration of SPK-8011QQ, currently in a Phase IIb trial.

Tovo David: F Hoffmann-La Roche Ltd - Current equity holder in publicly-traded company; Cerus Corporation - Patents & Royalties; F Hoffmann-La Roche Ltd - Patents & Royalties; F Hoffmann-La Roche Ltd - Current Employment